The news is directly about Merck & Co and is likely to influence investor sentiment. The lowering of the price target might suggest a slightly less optimistic outlook, but the maintained 'Buy' rating indicates that the analyst still sees potential in the stock. This could lead to mixed reactions in the market, hence the neutral score.